Abbott raises full-year 2026 adjusted EPS guidance to $5.45–$5.60
Abbott raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58, after reporting second-quarter 2026 results. The company reported comparable sales growth of 4.8 percent in the quarter and second-quarter adjusted diluted EPS of $1.31. Abbott reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.
Key facts
- Full-year 2026 adjusted diluted EPS guidance raised to $5.45 to $5.60 from previous range of $5.38 to $5.58
- Second-quarter 2026 adjusted diluted EPS of $1.31
- Second-quarter 2026 comparable sales growth of 4.8 percent
- Full-year 2026 comparable sales growth guidance reaffirmed at 6.5% to 7.5%
- Second-quarter 2026 reported sales growth of 13.0 percent
- Abbott returned $2.1 billion to shareholders in the second quarter in dividends and share repurchases
- Third-quarter 2026 adjusted diluted EPS guidance of $1.38 to $1.46
Why it matters
The raised EPS guidance reflects Abbott's confidence in accelerating sales and earnings growth for the second half of 2026, driven by momentum in diagnostics (including the Exact Sciences acquisition completed in March 2026), medical devices, and established pharmaceuticals.
Share
Derived from 8-K filed 2026-07-16. Not investment advice. View the source filing on SEC.gov →